These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 609579)

  • 21. Comparison of short and long-lasting effects of pargyline on cerebral dopamine metabolism.
    Waldmeier PC; Maître L
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Aug; 294(2):133-40. PubMed ID: 1012333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcium-independent release of [3H]dopamine by veratridine in pargyline- and reserpine-treated corpus striatum.
    Liang NY; Rutledge CO
    Eur J Pharmacol; 1983 Apr; 89(1-2):153-5. PubMed ID: 6861884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of reserpine on the incorporation in vivo of radioactivity from labeled serotonin and other 5-hydroxy-indole derivatives in mouse brain.
    Alivisatos SG; Ungar F; Seth PK; Levitt LP
    Biochem Pharmacol; 1970 Feb; 19(2):401-10. PubMed ID: 5515417
    [No Abstract]   [Full Text] [Related]  

  • 24. Lack of effect of intraventricular 6-hydroxydopamine pretreatment on rat striatal cholinergic parameters.
    Consolo S; Ladinsky H; Peri G; Samanin R; Ghezzi D
    Brain Res; 1974 Sep; 78(2):327-30. PubMed ID: 4852633
    [No Abstract]   [Full Text] [Related]  

  • 25. Prevention by calcium administration of reserpine action on rat brain noradrenaline stores: a reappraisal.
    Manara L; Cerletti C; Mennini T
    Res Commun Chem Pathol Pharmacol; 1976 Jul; 14(3):471-87. PubMed ID: 959653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects of intraventricular administration of 6-hydroxydopamine on behavior of rats in approach and avoidance procedures: Reversal of avoidance decrements by diazepam.
    Beer B; Lenard LG
    Pharmacol Biochem Behav; 1975; 3(5):879-86. PubMed ID: 1208630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Central muscarinic receptor degeneration following 6-hydroxydopamine lesion in mice.
    Gurwitz D; Kloog Y; Egozi Y; Sokolovsky M
    Life Sci; 1980 Jan; 26(1):79-84. PubMed ID: 7360000
    [No Abstract]   [Full Text] [Related]  

  • 28. Relationship of brain monoamine and locomotor activity in rats.
    Foldes A; Costa E
    Biochem Pharmacol; 1975 Sep; 24(17):1617-21. PubMed ID: 1191320
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative effects of 6-hydroxy-dopamine and of reserpine on quabain toxicity in the rat.
    Nadeau R; de Champlain J
    Life Sci; 1973 Dec; 13(12):1753-61. PubMed ID: 4777334
    [No Abstract]   [Full Text] [Related]  

  • 30. Central serotonin level-dependent changes in body temperature following administration of tryptophan to pargyline- and harmaline-pretreated rats.
    Abdel-Fattah AF; Matsumoto K; Murakami Y; Adel-Khalek Gammaz H; Mohamed MF; Watanabe H
    Gen Pharmacol; 1997 Mar; 28(3):405-9. PubMed ID: 9068981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amphetamine reduction of motor activity in rats after neonatal administration of 6-hydroxydopamine.
    Sorenson CA; Vayer JS; Goldberg CS
    Biol Psychiatry; 1977 Feb; 12(1):133-7. PubMed ID: 836921
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of catecholamine-depleting drugs and amphetamine on self-stimulation of brain following various 6-hydroxydopamine treatments.
    Cooper BR; Cott JM; Breese GR
    Psychopharmacologia; 1974 Jul; 37(3):235-48. PubMed ID: 4851731
    [No Abstract]   [Full Text] [Related]  

  • 33. The influence of central chemical sympathectomy and reserpine on peripheral effects of noradrenaline and cyclic AMP dibutyrate injected into the cerebral ventricles.
    Brus R; Herman ZS; Dzikowski A; Zabawska J
    Arch Immunol Ther Exp (Warsz); 1976; 24(4):537-42. PubMed ID: 187139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices.
    Fitzgerald JL; Reid JJ
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Mar; 347(3):313-23. PubMed ID: 8097569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of tyrosine hydroxylase and dopamine-beta-hydroxylase inhibition with the effects of various 6-hydroxydopamine treatments on d-amphetamine induced motor activity.
    Hollister AS; Breese GR; Cooper BR
    Psychopharmacologia; 1974 Mar; 36(1):1-16. PubMed ID: 4151923
    [No Abstract]   [Full Text] [Related]  

  • 36. Habituation failure of skin conductance response after intraventricular administration of 6-hydroxydopamine in cats.
    Yamamoto K; Hagino K; Moroji T; Ishii T
    Experientia; 1984 Apr; 40(4):344-5. PubMed ID: 6425074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of 6-hydroxydopamine on the antinociceptive action of morphine.
    Slater P; Blundell C
    Eur J Pharmacol; 1978 Apr; 48(3):237-47. PubMed ID: 639852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of central catecholamine alterations by 6-hydroxydopamine on shuttle box avoidance acquistion.
    Cooper BR; Breese GR; Howard JL; Grant LD
    Physiol Behav; 1972; 9(5):727-31. PubMed ID: 4655165
    [No Abstract]   [Full Text] [Related]  

  • 39. The in vivo binding of [3H]-desipramine and [3H]-chlorpromazine to areas in the rat brain.
    Yavin Z; Biegon A; Segal M; Samuel D
    Eur J Pharmacol; 1978 Sep; 51(2):121-7. PubMed ID: 699978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of intracerebral injections of 6-hydroxydopamine on sleep and waking in the rat.
    Lidbrink P; Fuxe K
    J Pharm Pharmacol; 1973 Jan; 25(1):84-7. PubMed ID: 4146210
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.